AltruBio Announces First Patient Dosed in Phase 1b Study of Neihulizumab in Patients with Steroid-Refractory Acute Graft-versus-Host Disease.
AltruBio Inc. moves forward with clinical development of Neihulizumab in Steroid-Refractory Acute Graft-versus-Host Disease after encouraging Phase 1a results
AltruBio Inc. presented AbGn-107 Phase 1a chemo-refractory GI cancer results at ASCO-GI 2020
AltruBio’s presentation on Neihulizumab Phase 2a Ulcerative colitis results selected as Poster of Distinction at Digestive Disease Week (DDW) 2020
AbGenomics Holding Inc. Announces Company Name Change to AltruBio Inc.
Bayer site head in Berkeley jumps to Peninsula cancer drug developer